Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Core Insights - Novo Nordisk has announced the presentation of subcutaneous amycretin data at the American Diabetes Association (ADA) 85 Scientific Sessions, highlighting its potential as a treatment for obesity and overweight [1][7][9] - Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism in a single molecule, which may offer complementary effects on appetite control [6][10] Clinical Trial Results - The phase 1b/2a clinical trial for once-weekly subcutaneous amycretin showed significant weight loss compared to placebo across all doses tested, with no plateauing observed at the end of treatment [2][3] - Estimated mean weight changes from baseline after treatment durations were as follows: - 60 mg for 36 weeks: -24.3% vs. placebo -1.1% - 20 mg for 36 weeks: -22.0% vs. placebo 1.9% - 5 mg for 28 weeks: -16.2% vs. placebo 2.3% - 1.25 mg for 20 weeks: -9.7% vs. placebo 2.0% [3][4] Safety and Tolerability - The safety profile of subcutaneous amycretin was consistent with other GLP-1 and amylin receptor agonists, with treatment-emergent adverse events (TEAEs) primarily being mild to moderate and gastrointestinal in nature [5][8] - The once-daily oral amycretin also demonstrated an acceptable safety profile, with TEAEs occurring in a dose-proportional manner and no new safety signals identified [8][9] Future Development - Based on the encouraging findings from both oral and subcutaneous amycretin trials, Novo Nordisk plans to advance amycretin into phase 3 trials to further assess its potential as a therapeutic option for weight management [9][10]